Auster Martin 4
4 · Ventyx Biosciences, Inc. · Filed Jul 26, 2023
Insider Transaction Report
Form 4
Auster Martin
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-07-25$3.45/sh+28,000$96,600→ 75,649 total - Exercise/Conversion
Stock Option (right to buy)
2023-07-25−28,000→ 219,184 totalExercise: $3.45Exp: 2031-05-06→ Common Stock (28,000 underlying) - Sale
Common Stock
2023-07-25$35.54/sh−28,000$995,044→ 47,649 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2022.
- [F2]Represents the weighted average share price of an aggregate total of 28,000 shares sold in the price range of $35.23 to $35.97. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one third (1/3rd) of the shares subject to the options shall vest on the one year anniversary of the Vesting Commencement date, and, thereafter, one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 3, 2021.